Head-To-Head Contrast: Adverum Biotechnologies (NASDAQ:ADVM) versus Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Invivyd and Adverum Biotechnologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	0	0	4	1	3.20
Adverum Biotechnologies	0	1	5	0	2.83

Invivyd presently has a consensus target price of $7.89, suggesting a potential upside of 967.90%. Adverum Biotechnologies has a consensus target price of $27.83, suggesting a potential upside of 397.02%. Given Invivyd’s stronger consensus rating and higher possible upside, equities analysts plainly believe Invivyd is more favorable than Adverum Biotechnologies.

Profitability

This table compares Invivyd and Adverum Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivyd	N/A	-155.33%	-114.88%
Adverum Biotechnologies	N/A	-65.14%	-40.52%

Insider & Institutional Ownership

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 17.9% of Invivyd shares are owned by insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Invivyd and Adverum Biotechnologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$11.56 million	7.64	-$198.64 million	($1.96)	-0.38
Adverum Biotechnologies	$1.00 million	116.49	-$117.17 million	($5.99)	-0.93

Adverum Biotechnologies has lower revenue, but higher earnings than Invivyd. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Invivyd has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Summary

Invivyd beats Adverum Biotechnologies on 8 of the 14 factors compared between the two stocks.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.